Skip to main contentSkip to navigation
Sirius Investors
AlloVir, Inc.

AlloVir, Inc.

ALVR
NASDAQHealthcare

AlloVir, Inc. (ALVR) Investment Research Dashboard

About AlloVir, Inc. (ALVR) stock analysis

Get live ALVR stock price $9.81, comprehensive AlloVir, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ALVR stock data and investment insights.

9.81
4.14%Today
Market Cap
49.48M
Volume
9.40K
52W High
24.15
52W Low
7.96

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral ...

Company Information

CEO
Vikas Sinha CPA,
Sector
Healthcare
Industry
Biotechnology
Employees
6

Contact Information

Address
1100 Winter Street
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.62) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for AlloVir, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for AlloVir, Inc.
  • Investors should consider how AlloVir, Inc. fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

49.48M

P/E Ratio (TTM)

-0.84

Beta

0.62

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

80/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+5.7%+6.1%19.3
98/100⭐⭐⭐⭐⭐
Communication Services+1.4%+2.9%+4.3%22.2
86/100⭐⭐⭐⭐⭐
Healthcare+0.7%+3.3%+3.5%24.1
80/100⭐⭐⭐⭐⭐
Basic Materials+0.4%+1.1%-0.2%25.2
56/100⭐⭐⭐⭐
Consumer Defensive-0.2%+1.7%+1.2%29.7
56/100⭐⭐⭐⭐
Real Estate-0.5%-0.1%-1.6%29.2
43/100⭐⭐⭐
Energy-2.1%-5.8%-5.1%19.1
39/100⭐⭐
Utilities-1.0%-3.0%-5.9%26.8
28/100⭐⭐
Industrials+0.6%+1.7%-11.2%30.1
26/100⭐⭐
Consumer Cyclical+0.5%-0.4%-6.3%43.0
21/100
Technology+0.6%-2.3%-9.6%40.7
17/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.